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Abstract: Antimicrobial stewardship (AMS) has emerged as a systematic approach to optimize
antimicrobial use and reduce antimicrobial resistance. To support the implementation of AMS
programs, the World Health Organization developed a draft toolkit for health care facility AMS
programs in low- and middle-income countries. A feasibility study was conducted in Bhutan,
the Federated States of Micronesia, Malawi, and Nepal to obtain local input on toolkit content and
implementation of AMS programs. This descriptive qualitative study included semi-structured
interviews with national- and facility-level stakeholders. Respondents identified AMS as a priority
and perceived the draft toolkit as a much-needed document to further AMS program implementation.
Facilitators for implementing AMS included strong national and facility leadership and clinical staff
engagement. Barriers included lack of human and financial resources, inadequate regulations for
prescription antibiotic sales, and insufficient AMS training. Action items for AMS implementation
included improved laboratory surveillance, establishment of a stepwise approach for implementation,
and mechanisms for reporting and feedback. Recommendations to improve the AMS toolkit’s content
included additional guidance on defining the responsibilities of the committees and how to prioritize
AMS programming based on local context. The AMS toolkit was perceived to be an important asset
as countries and health care facilities move forward to implement AMS programs.
Keywords: antimicrobial resistance; antimicrobial stewardship; low- and middle-income countries;
barriers and enablers
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1. Introduction
The misuse of antimicrobials is one of the main drivers for the development of antimicrobial
resistance (AMR) [1,2]. Antimicrobial stewardship (AMS) programs have been shown to be effective in
reducing unneeded antimicrobial use and slowing AMR in high-income countries; however, there are
limited data on the feasibility of AMS programs in low- and middle-income countries (LMIC) [3–6].
As a response, the World Health Organization (WHO) has developed a practical toolkit for health care
facility-based AMS programs in LMIC (hereafter referred to as the “AMS toolkit”) [7].
In 2015, at the 68th World Health Assembly, AMR was recognized as a threat to public health.
A global action plan, including an objective to optimize the use of antimicrobials, was endorsed during
the Assembly. AMS programs aim not only to optimize antimicrobial use, but also to improve patient
outcomes, decrease rates of AMR, and reduce health care costs [8–11]. With few new antimicrobials
being produced and the decreased effectiveness of existing antimicrobials, AMS programs are an
essential component of a One Health approach to address AMR [12]. Many LMIC have inadequate
AMS policies and treatment guidelines at both the national and health care facility levels, resulting in
a disproportionate impact of AMR in these countries [1,2,11,13–15]. Intraregional, interdisciplinary
collaborations and partnerships are needed at the national and facility level to adapt, implement, and
disseminate AMS programs that are locally salient [16–18].
The AMS toolkit is divided into six sections: (1) Structural Core Elements for AMS Implementation
at the National Level; (2) Structural Core Elements for AMS Implementation at the Facility Level;
(3) Planning AMS programs; (4) Performing AMS interventions; (5) Assessing AMS programs;
(6) Education and Training. As part of the AMS toolkit’s development, a feasibility study was
undertaken in Bhutan, the Federated States of Micronesia (FSM), Malawi, and Nepal. The study
objectives were to (1) assess local knowledge and perceptions regarding AMR, AMS, and key concepts
of the AMS toolkit; (2) identify barriers and facilitators for the implementation of AMS programs and
policies; (3) identify recommendations to revise the AMS toolkit draft to ensure it meets the needs of
a broad range of LMIC settings; (4) to provide recommendations to the countries on initiating and
strengthening AMS programs. The study countries were selected based on geographic regions where
AMR is a significant issue and where, to date, there are limited resources and AMS programs. These
countries also represent different regions and varying healthcare systems (Table 1).
Table 1. Information on Health Care Systems, AMR Stewardship, and Pharmaceutical Sales by Country.
Country/Population

Country-Specific Details

Bhutan
727,000

Health Care System: Majority public funded health system with some private
providers. The National Health System provides free health care, including
pharmaceuticals.
AMR Stewardship: The Bhutan NAP on AMR was launched by the Bhutan cabinet
in May 2017. AMS is prioritized in the NAP; a hospital-based AMS program has been
initiated and the National Referral Hospital will function as the National AMS
Coordination Center.
Pharmaceutical Sales: Sales of antimicrobials by prescription-only is regulated by
the Drug Regulatory Authority and the ban of irrational fixed-dose combinations
(FDCs) is consistent with the WHO restricted list of FDCs.

Federated States of
Micronesia (FSM)
100,000

Health Care System: There is one public hospital within each of the four island
states and a fifth private hospital on the island of Pohnpei. The Department of Health
Services in each state provides medical and public health services through a hospital,
community health centers, and dispensaries. Each state system is autonomous.
Health services are highly subsidized by the state governments, except in private
clinics. There are six private health clinics in the country and one private hospital.
Transportation difficulties between islands often prevent outer island residents from
accessing hospital services.1
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Table 1. Cont.
Country/Population

Country-Specific Details
AMR Stewardship: The NAP on AMR in FSM has been drafted, but not yet
implemented country-wide. A technical working group (TWG) comprised of
national-level policymakers has worked on the implementation of the NAP, but it has
not yet been endorsed by Congress. An AMS program across hospitals and other
community health facilities has been identified as a priority in the NAP.
Representatives from each of the four states have also worked on the revising and
editing of the NAP to make it applicable across the entirety of FSM.
Pharmaceutical Sales: A bill on prescription-only regulation of all antibiotic sales is
currently under advisement in the National Congress. Many patients within FSM are
served by community dispensaries, particularly in the outer islands of the region
where few qualified healthcare professionals are practicing. These dispensaries are
undergoing a review of standards. Antibiotic purchasing is handled at the state level,
guided by the National Essential Medicines List. When antibiotic inefficacy is
suspected, quality control testing is undertaken in connection with the Therapeutic
Goods Administration in Australia.

Malawi
18.6 million

Nepal
26 million

Health Care Services: Health services in Malawi are provided by public, private for
profit (PFP), and private not for profit (PNFP) sectors. Health services in the public
sector are free-of-charge at the point of use. The PFP sector consists of private
hospitals, clinics, laboratories, and pharmacies. Traditional healers are also prominent
and would be classified as PFP. The PNFP sector comprises of religious institutions,
nongovernmental organizations (NGOs), statutory corporations and companies.2
AMR Stewardship: In 2015, a situational analysis of AMR was undertaken by the
Ministry of Health. In 2017–2018, a NAP on AMR based on a One Health approach
was developed and approved.
Pharmaceutical Sales: Regulations to restrict nonprescription sale of antibiotics are
limited and antibiotics are readily available in communities throughout Malawi.
There are national-level guidelines, which were implemented in 2014; however, there
is a need for revision to reflect the specific patterns of resistance throughout Malawi.
A majority of antibiotics are prescribed without any definitive laboratory data on
pathogen or resistance. Hospitals are dependent on donations for many
pharmaceuticals, including antibiotics, and certain antibiotics may be overprescribed
because of limited options.
Health Care System: Nepal’s health system includes public, private, and
not-for-profit facilities. As part of the new federalist government system’s
restructuring, the public health system is being decentralized, with 16 tertiary
hospitals being managed by the federal government and primary and secondary
hospitals being managed at the provincial level. At the same time, the Ministry of
Health and Population (MOHP) is expanding access to Universal Health Care
throughout the country.
AMR Stewardship: The MOHP has also established a multisector AMR Steering
Committee inclusive of a TWG, which has been approved by the Deputy Prime
Minister. As of 2019, a NAP on AMR has been drafted and includes AMS as a priority.
Pharmaceutical Sales: Regulations to restrict nonprescription sale of antibiotics are
limited, with little monitoring and enforcement of existing policies. Many remote
areas do not have access to trained physicians, so other health providers must
dispense antibiotics in public health centers.

1

World Health Organization Western Pacific Region. 2017. Federated States of Micronesia: WHO Country
Cooperation Strategy, 2018-2022. 2 Ministry of Health and Population, Republic of Malawi. The Health Care System.
Available at: https://www.health.gov.mw/index.php/2016-01-06-19-58-23/national-aids.

2. Results
The following results are organized by national and health care facility core elements and health
care facility-based interventions as described within the AMS toolkit. In addition, we have included
data on actionable items and recommendations for the draft toolkit. A summary of demographic
information is found in Table 2.
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Table 2. Clinical Staff Demographics.
Bhutan

Federated States
of Micronesia

Malawi

Nepal

-

16

21

16

12

Yes

10

5

9

6

No

6

12

2

5

No IPC at
institution

-

3

3

1

No response

-

1

2

-

Average years at
institution

-

8.0 (range 2–19)

14.2 (range
0.33–30)

7.2 years (range
0.75–14)

15.4 (range
1–35)

Average years
working on AMR

-

6.9 (range 1–28)

9.8 (range 1–26)

5.1 years (range
0.33–21)

6.4 (range
1.5–20)

Facility
classification

Public

16

20

16

5

Private

0

1

0

4

Non-profit

-

-

-

3

Demographic Description
Total staff
interviewed
Members of IPC
committee

AMR—antimicrobial resistance; IPC—infection prevention and control.

Key findings from this study are shown in Table 3.
Table 3. Key findings for Implementation of AMS in LMIC.
Implementation Category
AMS implementation facilitators

AMS implementation barriers

Key Findings
•
•

Strong national and health care facility leadership.
Clinical staff engagement in AMS committees.

•
•

Inadequate human and financial resources.
Limited supplies of antibiotics, particularly in
remote regions.
Lack of enforcement of regulations for prescription-only
sales of antibiotics.
AMS competencies among health care workers and
limited training and education in AMR, AMS, and IPC.

•
•

•
•
Recommendations to strengthen health
care facility-based AMS

•
•

Dedicated financial resources and AMS leaders
and champions.
Use of stepwise approaches for AMS implementation
based on country and health care facility contexts.
Mechanisms for reporting and feedback.
Implementation of interdisciplinary AMS training
workshops and AMS curricula.

AMR—antimicrobial resistance; AMS—antimicrobial stewardship; IPC—infection prevention and control.

2.1. National Core Elements
The national core elements include (1) National Plan and Strategies; (2) Regulations and Guidelines;
(3) Education and Training; (4) Supporting Technologies and Data.
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2.1.1. National Plan and Strategies
All study countries identified AMR as a growing threat and have drafted an AMR National Action
Plan (NAP); however, the countries were at various levels in terms of NAP implementation. Relatively
few respondents outside of the national government were aware of the NAP content.
Remark 1. “I have heard of the National Plan, but it is not being implemented in our medical college . . . .”
(Hospital Administrator, Nepal)
Study participants aware of the NAP reported dedicated high-level national leadership in support
of the NAP. In addition, some countries have obtained outside funding to support portions of the NAP.
However, across the four countries, numerous barriers were identified that affected the implementation
of NAP policies and programs. These barriers included the need for additional financial support and
technical assistance, limited laboratory capacity, including infrastructure and expertise, and lack of
technical expertise on AMR-specific issues.
Remark 2. “ . . . again, it involves a lot of resources. You need to see the sensitivity and (do) surveillance . . . to
review sensitivities . . . A lot of budget is involved in that. So, funding is another part (in terms of) feasibility or
not. And of course, the human side and human resources are also important....” (National Level, Nepal)
2.1.2. Regulations and Guidelines
Facilitators for AMR regulations and guidelines included the existence of drafted standard
antibiotic prescribing guidelines, which have been developed in Bhutan, Malawi, and Nepal. In FSM,
there is an antibiotic prescribing guideline that has been reviewed with national stakeholders
and external technical expertise. FSM, Malawi, and Nepal are in the process of developing and
implementing policies for prescription-only antibiotic sales. In Bhutan, prescription-only regulations
are implemented and enforced. The key barriers identified included inadequate monitoring and
evaluation at the national and regional levels for infection prevention and control (IPC) and AMS
including adherence to guidelines, inadequate laboratory facilities to provide empiric diagnostic data
and support, implementation of the AWaRe (Access, Watch, Reserve) classification of antibiotics,
challenges with the supply chain of medications in hospital pharmacies, and lack of prescribers
(physicians) in remote areas.
Remark 3. “ . . . .I’m not claiming that just writing in law will be sufficient to really restrict prescriptions for
selling . . . we have so many pharmacies which have been already selling without prescriptions . . . we need to
really go and then take action against those who are selling the antibiotics . . . at the same time in the public
sector we are promoting some antibiotics to be used by [non-physicians] . . . because neonatal mortality [is] very
high . . . ” (National Level, Nepal)
Remark 4. “ . . . If we don’t have the drugs [in the hospital], the doctor will prescribe and then the patient is
obligated to buy in a pharmacy . . . .” (National Level, Malawi)
2.1.3. Awareness, Training, and Education
At the national level, there was strong support to enhance education and training in AMR/AMS for
physicians, nurses, pharmacists, and laboratory staff. At the broader community level, AMS awareness,
training, and education included public antibiotic information campaigns. Barriers included lack of
dedicated financial support and limited training and technical expertise. Respondents also reported
the need for more community advocacy and awareness of AMR.
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Remark 5. “ . . . and we are also thinking to develop some sort of dramatizing . . . learning materials and
publishing to the media (for the community). So that type of materials we’re planning to do. That requires a
little bit budget so we are constrained with budget so we’re planning anyway . . . and also planning to do some
training for health professionals . . . primary, community levels–upper-level health professionals also need to
have training . . . .” (National Level, Nepal)
2.1.4. Supporting Technologies and Data
Bhutan, Malawi, and Nepal are recipients of Fleming Fund grants to expand microbiology
laboratory capacity and strengthen surveillance systems [16]. Respondents perceived this support as a
starting point to significantly enhance NAP implementation. However, respondents also recognized
the need for more sustained funding and training in diagnostic testing, laboratory surveillance, and
information technologies, and the struggle with inadequate local expertise in monitoring antimicrobial
use and consumption.
Remark 6. “So, we are so glad that at least one of our key priorities for the NAP–AMR surveillance—we have
a country grant to support improving lab capacity and surveillance. So, that’s a very good plus for us . . . .”
(National Level, Malawi)
2.2. Health Care Facility Core Elements
Health care facility core elements include (1) Leadership Commitment; (2) Accountability
and Responsibilities; (3) Education and Training; (4) Monitoring and Surveillance; (5) Reporting
and Feedback.
2.2.1. Leadership Commitment
A key component of facility-based AMS is dedicated support from facility leadership to encourage
the development of AMS and IPC committees and implement programs. Facility leaders stated that
the recommended AMS activities in the toolkit are feasible and necessary to decrease AMR. Barriers
to leadership commitment included inadequate dedicated human and financial resources for AMS
programs, and inadequate internal communication between administrators, management, and staff.
Remark 7. “A successful stewardship program can only work when there is good collaboration between top
management and middle-level management. Because middle-level management, they are the ones that are in
touch with the staff on the ground there.” (Hospital Administrator, Malawi)
Remark 8. “Stressing the importance of leadership commitment is really important. Because nothing really
happens without leadership commitment.” (National Level, FSM)
2.2.2. Accountability and Responsibilities
Respondents described active IPC committees, quality improvement teams, and drug and
therapeutic committees. These committees are engaged in routine activities and provide important
feedback and training to clinical personnel. Building on these committees, leaders and clinical staff were
enthusiastic about future implementation of AMS committees and antibiotic prescribing guidelines.
Remark 9. “ . . . we don’t have an AMS team but the infection control committee they have nurse staff. They do
regular monitoring of cultures of different areas of the theatre . . . they take a routine culture on a regular basis
. . . .” (Hospital Administrator, Nepal)
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Barriers included physicians’ reluctance to change their prescribing practices, even with the
available evidence-based guidelines, and provider-heavy workloads, which decreased interest in
devoting time to an AMS committee.
Remark 10. “We have an issue of shortages of staff . . . we also have issues of people wearing too many hats,
so that is part of, I guess, it’s kind of like we’re not sure who’s going to take care of it, and wonder who which
program is.” (Clinical Staff, FSM)
2.2.3. Education and Training
There was a high level of enthusiasm for expanding AMS education and training within health care
facilities. Currently, some study facilities have an established education infrastructure (e.g., continuing
medical education) that can support additional AMR/AMS training. However, despite enthusiasm,
time and resources were barriers. Many facilities lack space and available expertise to support
trainings. At some sites, even IPC trainings are limited due to inadequate resources. In addition, some
respondents emphasized the need for a ‘hands-on’ approach to support sustained knowledge.
Remark 11. “Major barriers as of right now is lack of knowledge mainly. We have high staff turnover, so in the
last three years there have been no new trainings. Almost 75% of the staff may not be aware of the IP (infection
prevention) practices . . . .” (Clinical Staff, Malawi)
Remark 12. “So hands-on is a very, very important part of it. As compared to just reading and looking at the
modules. But you have to apply, the application of that knowledge needs to be implemented as well. With the
hands-on skills I think it will stick and will stay there longer, and be more useful to the people. In my opinion,
I think two or more models of education is probably the best suitable for us in this setting.”
2.2.4. Monitoring and Surveillance
Among microbiologists and laboratory staff, there was a strong desire for capacity building and
international support for up-to-date equipment and supplies and development of AMR surveillance
systems. However, in most health care facility sites, there was inadequate capacity to conduct
point prevalence surveys and routine surveillance of susceptibility patterns, including health care
facility-specific antibiogram data.
Remark 13. “For the lab, our major challenges are both human and material resources . . . we have a very
big challenge procuring laboratory microbiology supplies. Either maybe because of the budget or our major
supplier—the central medical stores—they don’t have them in stock . . . . . . we have the knowledge, but resources
are not there . . . .” (Clinical Staff, Malawi)
2.2.5. Reporting and Feedback
In health care facilities with developed IPC committees, there are existing reporting and feedback
structures in place that can be expanded to include AMS. However, in most facilities, there are inadequate
structures for reporting these data to facility management and clinical staff. Study participants noted
there was little communication between laboratory and clinical personnel, decreasing opportunities
for information exchange about AMR patterns and impact of the use of specific antibiotics.
Remark 14. “ . . . We are very much lacking in reporting and feedback. We can do something but this is one area
we really have to really have to think and discuss with regards to core elements . . . there are so many challenges,
which we have to sit together and discuss and see how to move things forward.” (Clinical Staff, Bhutan)

Antibiotics 2020, 9, 556

8 of 16

2.3. Action Items at the National and Health Care Facility Level
Multiple action items were identified at both the national and facility level to move forward with
implementation of the NAP and the WHO toolkit and development and implementation of AMS
committees and other supporting programs and policies. Identification of sustainable funding and
technical expertise in human, animal, and environmental health was essential across each of the core
elements. Action items at the national and facility level are found in Boxes 1 and 2.
Box 1. National-level action items to support AMS and toolkit implementation.
•
•
•
•
•
•
•
•
•

Establish terms of reference for National AMR technical working groups.
Perform needs assessments of local laboratory capacity at the national and local levels.
Update National Essential Medicine Lists or equivalent documents, including integration of the WHO
AWaRe categories.
Sensitize health care providers about AwaRE categories.
Review, update, and implement national and district/state/regional antibiotic prescribing guidelines
informed by available AMR surveillance data.
Develop needed resources for health care facility leadership to ensure antibiotic prescribing guidelines are
followed consistently across the country.
Increase national antibiotic awareness campaigns.
Develop or expand age-relevant education AMR/AMS programs in public school systems.
Strengthen microbiology laboratory capacity and expand training to facility-based laboratory staff to
support and encourage engagement in AMS and national surveillance.
AMR—antimicrobial resistance; AMS—antimicrobial stewardship.

Box 2. Health care facility-level action items to support AMS and toolkit implementation.
•
•
•
•
•
•

•
•
•
•
•
•

Identify funding sources to support facility-level AMS.
Sensitize facility leaders about the urgency of AMR as a health risk.
Increase facility leaders’ awareness of National Action Plan (NAP) content, government roll out plans, and
potential funding and resources to support facility-based AMS.
Develop stepwise approaches to implement AMS considering facility capacities throughout the country.
Standardize IPC committee roles and responsibilities.
Identify dedicated leaders and champions within facilities who will take responsibility for establishing
AMS committees and implement AMS programs. In many instances, individuals involved in IPC, QIT, and
DTC committees can serve as key stakeholders in this process.
Develop/adapt standard antibiotic prescribing guidelines informed by local AMR surveillance data patterns.
Strengthen laboratory capacity to ensure annual output of aggregate antibiograms and support regular
reporting to national laboratories for AMR surveillance.
Establish mechanisms for reporting and feedback on the implementation of AMS interventions and
adherence to antibiotic prescribing guidelines based on international consensus and local input.
Integrate AMS training into existing CME programs and IPC training initiatives across all health disciplines.
Develop interdisciplinary training programs to support increased understanding and communication
between wards and departments.
Develop training-of-trainer workshops on AMS and cascade training to other health care providers in the
health care facilities.

AMR—antimicrobial resistance; AMS—antimicrobial stewardship; CME—continuing medical education;
DTC—drug and therapeutic committees; IPC—infection prevention and control; QIT—quality
improvement teams.

2.4. Health Care Facility-Based AMS Interventions
The WHO toolkit provides a detailed overview of evidence-based health care facility AMS
interventions including (1) persuasive, educational, and feedback; (2) restrictive; (3) structural
interventions. The toolkit also includes information on planning, implementing, and assessing AMS
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programs. Identified enablers to support AMS interventions included strong leadership support at
the health care facility administration level, overall strong interest in education and training in IPC,
AMR, and AMS among clinical staff, and perceptions among staff that AMS interventions decrease
unnecessary antibiotic use. Barriers included inadequate local infectious disease, AMR and AMS
expertise, and limited financial and human resources to implement interventions and conduct program
monitoring and evaluation.
Remark 15. “When it comes to interventions I think they are very much appropriate because many of these
problems do exist in our . . . day-to-day practices. But we are not really assessing them . . . to the fullest extent
about the interventions.” (Clinical Staff, Bhutan)
2.5. Summary of Recommendations for the Draft WHO Toolkit
Study participants suggested recommendations on the improvement of content, organization,
and presentation of materials, which were incorporated into the final version of the WHO AMS toolkit
(Table 4). Participants also noted that the review of the AMS toolkit needs to be an iterative process as
implementation of the toolkit and AMS programs and policies progress in each country.
Table 4. Key recommendations and implemented changes in the WHO AMS toolkit
Study Participants’ Recommendations
Easy-to-follow directions in terms of which
chapters were most relevant for specific
audiences
Additional information on how to prioritize
AMS activities (short-, medium-, and
long-term) and guidance on stratification of
interventions and assessment procedures
based on local resources.
Guidance in prioritizing AMS activities
based on available resources, establishing
stronger linkages between existing
programs, e.g., IPC and AMS, and
instituting the roles and responsibilities of
members of AMS committees.

Definition of the role and function of an
AMS champion. Definition of roles within
AMS interventions for various types of
health providers (e.g., physician, nurse, and
microbiologist).

Specific Changes to Toolkit
Key target audience was added

Toolkit Reference
Top of first page of all
chapters

•

Key steps in establishing a
national AMS program to
enable facility AMS;
Key steps to establishing a
health care facility
AMS program;
Indicators from the Tripartite
M&E framework for the
Global Action Plan on AMR
relevant to AMS programs;
Preparation for developing
and implementing an AMS
program in a health
care facility;
Sample AMS review form.
Sample terms of reference
national AMS technical
working group;
Sample terms of reference
health care facility
AMS committee;
Sample terms of reference
health care facility AMS team.

Ch. 1, Page 3, Box 1

Snapshot of GLASS;
Sample
pre-authorization/restricted
prescribing form;
Sample medical chart;
Sample bug–drug chart;
Sample cumulative
antibiogram for
Gram-negative bacteria;

Ch. 4, Page 29, Box 7
Page 68, Annex V

•

•

•

•
•

•

•

Information or resource links that can guide
countries in the development of AMS and
AMR antibiotic prescribing guidelines in
regions without hospitals and physicians.

•
•

•
•
•

Ch. 1 Page 4, Box 2

Ch. 2, Page 10, Table 3

Ch. 4, Page 18, Table 5

Page 67, Annex IV
Page 63, Annex I

Page 64, Annex II

Page 66, Annex III

Page 69, Annex VI
Page 70, Annex VII
Page 71, Annex VIII
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Table 4. Cont.
Study Participants’ Recommendations
Training information to support effective
AMS and IPC committees in terms of
leadership skills, division of staff roles and
responsibilities, reporting and feedback
systems, and interdisciplinary
communication.

•
•

•
•
•

Specific Changes to Toolkit
Core components of IPC and
the link to AMS;
Step-by-step guide for setting
up an AMC surveillance
program at the facility level;
Step-by-step guide for setting
up a health care facility PPS;
The quality improvement
model in more detail;
Core steps for implementing
an educational program.

Toolkit Reference
Ch. 4, Page 23, Box 4
Ch. 4, Page 25, Box 5

Ch. 4, Page 26, Box 6
Ch. 5, Page 34, Figure 15
Ch. 7, Page 60, Box 9

Remark 16. “I think it’s a good start. It has more stuff, areas that need to be stringent, if we kind of have an
impact on this issue. And I think it’s pretty comprehensive in a sense . . . But I think it should be an organic
process, as we move along and identify issues, we address them and continue to make improvements.” (Clinical
Staff, FSM)
3. Discussion
The toolkit was universally well-received by policy makers, facility management, and clinical
staff levels throughout the four study countries. Data were obtained from a diverse multinational and
interdisciplinary group of stakeholders. Identification of possible enablers and barriers for toolkit
implementation at the national and facility level supported revisions to ensure that the toolkit meets the
needs of a broad range of LMIC settings. Each study country presented different contextual factors to
consider regarding AMS implementation and use of the AMS toolkit. Varying factors included different
health priorities at both the national and facility level, current status of nationalized universal health
care plans, variances in public health funding, availability and use of antibiotics, and development and
enforcement of prescription-only regulations. These factors must be considered on a country-by-country
basis for stakeholder engagement and evaluating pathways to toolkit implementation.
Key facilitators and enablers included strong leadership commitment at the national, local, and
facility levels, increases in funding mechanisms to support development of surveillance systems within
countries, and increased awareness of AMR. Key barriers to AMS implementation included limited
human and financial resources, inadequate supporting technologies (e.g., monitoring and surveillance),
and communication challenges between facility administration and staff, and between staff members.
These barriers can be mitigated using a clear step-by-step approach, as indicated in the WHO AMS
toolkit, tailored to specific country and facility contexts and needs. In addition, a multidisciplinary
training and education approach can potentially strengthen AMS commitment and communication
within health care facilities.
Prior studies have described the core elements of AMS programs in LMIC settings, including
the need to build laboratory capacity, enhance IPC, and establish surveillance systems of both
infections and antibiotic use [15,19–25]. Feasibility study data support these needs, as well as other
essential elements of AMS. Overall, respondents stated that leadership support at the national and
senior facility management levels was needed for successful implementation. In addition, stepwise
implementation strategies were universally considered to be useful. At the national level, respondents
supported the urgent need for the development and implementation of antibiotic treatment guidelines.
AMS must be identified as a national priority and included in facility key performance indicators,
requiring dedicated support, accountability, and assigned roles and responsibilities. Within health
care facilities, AMS must include written strategies, implementation of a formal multidisciplinary
structure including laboratory surveillance and IPC, and identification of dedicated staff with clearly
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defined roles. These strategies must include support and expertise on infection management, access
to timely laboratory/imaging/information technology services and available trained and experienced
professionals in AMR and infectious disease.
Respondents reported the need for increased and consistent education and training. A first
step towards strengthening educational initiatives includes understanding current clinical staff
competencies and building tailored projects and programs that emphasize and develop knowledge
and skills. Education must be ongoing, hands on, and practical, and include incentives and a broad
range of resources (e.g., face-to-face and web-based).
Respondents felt the toolkit provided important information on appropriate antibiotic use and
consumption and the means to utilize less expensive and technologically based approaches appropriate
to LMIC contexts. AMS committees were considered at the heart of effective facility-based stewardship.
Therefore, these committees must be formed and members must receive regular training in antimicrobial
prescribing practices and stewardship. The committee should be responsible for reviewing and auditing
courses of therapy for specified antimicrobial agents and clinical conditions. There is also the need for
an established and effective communication strategy between the AMS committee, leadership, and
clinical staff.
In terms of health care facility-based AMS, evidence-based antibiotic treatment guidelines were
identified as a key component of AMS. Where possible, guidelines should be based on local antibiotic
resistance patterns and availability and cost-effectiveness of agents. Day-to-day guidelines should
be kept simple and include empiric antibiotic selection, definitive antibiotic selection, organism and
disease states, intravenous to oral conversion, renal dosing, and duration of therapy. In conjunction
with those guidelines, AMS programs are needed to reduce the overuse and overprescribing of
antibiotics, the use of broad-spectrum antibiotics and dose combinations, and delayed prescribing.
Health care facilities in LMIC need capacity building both in terms of human and technological
resources to develop a formulary and auditing process, antibiotic prescribing documentation policies
and procedures, and regulations regarding drug restrictions including use of the WHO AWaRe (Access,
Watch, Reserve) classifications. Health care facility monitoring and surveillance capabilities need to be
developed to support AMS initiatives including measures to monitor quality/quantity of antimicrobial
use at the unit and facility-wide level, compliance with specific interventions, and identification of
antibiotic susceptibility rates for locally significant pathogens.
Limitations
The feasibility study was conducted in only four countries with a sample size of 12 national
leaders, 21 facility administrators, and 65 clinical staff. Only one country was selected from Africa and
there were no LMIC from Latin America, the Caribbean, the Middle East, or Europe included. Despite
the small sample size, purposeful sampling was undertaken to ensure that different regions of the
study countries were included with a diverse group of national- and facility-based stakeholders. These
data provide a general overview of barriers and facilitators for implementation of AMS programs and
the AMS toolkit. As implementation of the toolkit moves forward, additional data from other countries
will continue to contribute to future versions. In addition, the feasibility study was focused on health
facilities which provide inpatient care. Respondents discussed the need for AMS within community
health facilities and education for patients. Future research and development of community-based
AMS training and interventions are needed to address the high consumption of antibiotics outside of
inpatient facilities.
4. Materials and Methods
4.1. Overview
The feasibility study was conducted from February 2019 to May 2019. The project was a partnership
inclusive of a multinational and interdisciplinary team with expertise in AMR and AMS, infectious

Antibiotics 2020, 9, 556

12 of 16

diseases, IPC, public health, nursing sciences, pharmacy, and social sciences. The study countries were
selected by both WHO staff and the HFHS feasibility study team, based on geographic regions where
AMR is a significant issue and where, to date, there are limited resources and AMS programs. These
countries represent diverse contexts and challenges associated with the implementation of health care
facility-based AMS programs. In addition, WHO and/or HFHS had worked with AMS leaders in the
four selected countries, which facilitated rapid implementation of the feasibility study.
The study population included national- and local-level policymakers, facility administrators, and
clinical staff. Study health care facilities were identified by in-country investigators and coordinators,
and represented various facilities (e.g., public, private, and non-profit) and diverse geographic
regions within each country. All facilities included inpatient care and ranged in size from 36 to
850 beds. Participating clinical staff included physicians, nurses, pharmacists, microbiologists, and
laboratory technicians.
The study used a qualitative design based on key domains for program feasibility studies [26,27].
These included (1) acceptability of the toolkit; (2) demand and anticipated use; (3) practicality of the
toolkit for use in LMIC; (4) integration of the toolkit within existing infrastructures; (5) adaptability
of the toolkit within local contexts; (6) implementation and dissemination enablers and barriers to
toolkit sustainability and scale-up within LMIC. The qualitative approach provided opportunity to
engage with multiple partners from the selected sites throughout the development, implementation,
and dissemination of the study. Through this engagement, conversations about AMR during meetings,
workshops, and interviews provided visibility to local, national, and international issues related to
AMR, the role of stewardship in the contexts of LMIC, and the potential for adaptation of the WHO
toolkit to support AMR stewardship at the policy and programmatic levels in multiple settings.
In each country, the project was undertaken after an initial meeting with in-country study
investigators and local governmental, nongovernmental, and health care facility stakeholders. After
completion of the study, dissemination stakeholder workshops were convened within each country.
These workshops provided opportunity for local input on (1) the interpretation of the feasibility study
data; (2) ways to address facilitators and barriers to implementation of the AMS toolkit and AMS
programs and policies; (3) identification of actionable items to promote implementation. This input
from each country is reflected in the final reports and subsequently, in this paper.
4.2. Sample Size and Recruitment
Overall, 12 policy makers were recruited and interviewed, and 15 health care facilities were
selected between the four countries. With the facilities, a total of 21 administrators, 20 physicians,
21 nurses, 11 pharmacists, and 13 laboratory personnel were interviewed (Table 5). When the study
started, the research team estimated the sample size with the stipulation that it could be smaller or
larger depending on data saturation. In each site, the team felt confident that the data collected reached
saturation and no significant additional information was being recorded to justify additional interviews.
National-level respondents were identified by in-country principal investigators and coordinators
as well as recommendations from the WHO Country Offices and included individuals involved in the
development of AMS NAP and other experts in AMR and AMS. At the facility level, administrators or
managers were invited to participate in the study. Clinical staff selection criteria included individuals
engaged in current or past IPC programs and/or those engaged in existing AMS committees. A range
of staff were interviewed, including ward physicians and nurses, laboratory staff, and pharmacists.
In each country, the international and local partners worked closely together to approach potential
respondents to explain the purpose of the study and request their participation. At the policy and
hospital administration level, all of those approached made themselves available for the interviews.
At the clinical level, the study team requested interviews with representatives from nursing, medicine,
pharmacy, and microbiology/laboratory staff (Table 5). Potential participants were provided with
an abbreviated version of the toolkit with sections specific to their position (e.g., policy maker,
administrator, and staff) and a list of key topics to be covered in the interview [28].
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Table 5. Study sites, health care facility types, and sample sizes for policy makers, facility administrators,
and clinical staff.
Country
Bhutan

FSM

Malawi

Nepal

Location

Facility

Central

Public

Western

Public

Eastern

Public

Chuuk State

Public

Kosrae State

Public

Pohnpei State

Public

Yap State

Public

Lilongwe

Public

Lilongwe

Public

Mzuzu

Public

Blantyre

Public

Kathmandu

Non-profit

Kathmandu

Public

Nepalgunj

Private

Dharan

Private

-

-

TOTAL

Policy Makers

Administrators

Staff

3

5

6 physicians
4 nurses
3 pharmacists
3 laboratory

7

8 physicians
6 nurses
2 pharmacists
4 laboratory

5

3 physicians
6 nurses
4 pharmacists
4 laboratory

3

4

3 physicians
5 nurses
2 pharmacists
2 laboratory

12

21

20 physicians
21 nurses
11 pharmacists

3

3

4.3. Research Instruments
Three interview guides and demographic forms were developed specific to the population
groups (policymakers, health care facility administrators, and clinical staff). Draft interview guides
and demographic forms were provided to in-country investigators to review and revise to ensure
they reflected local contexts. Interview guide items and probes focused on the research objectives,
the toolkit core elements for health care facility-based AMS in LMIC, and the 6 program feasibility key
domains. Demographic forms included items on current institutional affiliation (e.g., city/district, type
of institution, and number of beds), respondents’ education and employment (e.g., current position
and years in current position), and engagement in AMR, AMS, and IPC programs at the health care
facility or national levels (see Table S1).
4.4. Data Collection and Management
Data collection was led by team members from the Henry Ford Health System in partnership
with local staff. In Bhutan, additional data collection support was provided by investigators/infectious
disease specialists from Christian Medical College, Vellore, India. Interviews were conducted in
English, with interpretation to local language verbally as required. Interviews were audiotaped and
transcribed. Transcribed data were entered into Ethnograph, version 6, a qualitative data management
software. A data coding dictionary was developed based on the interview guides and emergent themes
from team members’ field experiences and the transcribed text.
4.5. Data Analysis
After initial coding was completed, groups of code words were organized under common topics
including the AMS core elements, the key domains for the feasibility study, and emergent themes.
Searches were conducted within common themes, study country, and population (policymakers,
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administrators, and staff). Search documents were saved and reviewed to identify key findings and
recommendations within and across countries in terms of barriers and facilitators for health care
facility-based AMS policies and programs, action items to strengthen AMS policies and programs
including implementation of the AMS toolkit, and specific recommendations for the AMS toolkit’s
content and organization. Illustrative text within the transcripts were identified to support the summary
conclusions. Country-specific draft reports were sent to in-country investigators and other stakeholders
for their review and input.
4.6. Ethical Approval
The project was approved by ethical review boards in each country, the Henry Ford Health System
Institutional Review Board (Detroit, MI, USA), and the WHO Ethical Review Committee (Geneva)
(Approval February 2019, #ppp3131/004479)]. All participants provided written informed consent.
5. Conclusions
There was clear consensus that optimal implementation and use of the toolkit requires recognition
of country-specific contexts. These include diagnostic challenges, laboratory capacity, and high burdens
of infectious diseases. Health care workers responsible for prescribing antibiotics have a broad range
of education, training, and experience. Development of antibiotic prescribing guidelines may often
be limited by inadequate local data on disease burden and susceptibility patterns. Many LMIC have
poorly regulated prescription-only policies or limited access to essential antibiotics
Despite these challenges, the consensus among study respondents was that the toolkit will be an
important asset as countries and health care facilities move forward to combat AMR and implement
AMS programs. More information will be needed to address implementation strategies and many
barriers need to be addressed to increase likelihood of successful implementation within the study
countries and other LMIC. The road ahead must include commitment at the national and facility
levels to prioritize AMR and develop sustainable national and local initiatives. The WHO toolkit
provides a comprehensive review of core elements of AMS, strategies for intervention adaptation and
implementation, and expansion of training and educational platforms. With growing global concerns
regarding AMR, the WHO toolkit can provide practical guidance and support to LMIC worldwide [1].
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Table S1. Interview guides.
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